Accretion Nutraveda Reports Robust FY26 Results with 110% Sales Growth; Stock Gains 2%

Synopsis: Accretion Nutraveda Ltd came under investor focus after announcing its FY26 financial results along with key board-level changes. The company reported strong profit growth while two independent directors stepped down due to personal commitments.

In a regulatory filing submitted to the BSE, Accretion Nutraveda Limited announced several important corporate developments, including the approval of its audited financial results for FY26 and changes in the composition of its Board of Directors.

As part of the management restructuring, two independent directors Arun Dash and Mahipal Singh Chouhan ended their resignations from the board effective May 8, 2026. Both directors cited personal and professional commitments as the primary reason for stepping down from their roles. Consequently, they also relinquished their responsibilities as members and chairpersons of key committees, including the Audit Committee, Nomination and Remuneration Committee, and Stakeholder Relationship Committee.

The company clarified that there were no material reasons or governance concerns associated with their resignations. The outgoing directors expressed gratitude to the board and management for the cooperation extended during their tenure and conveyed their best wishes for the company’s continued growth.

Alongside these governance changes, the company also reported its audited financial performance for FY26, highlighting continued growth in its nutraceutical manufacturing operations.

For the full financial year ended March 31, 2026, Accretion Nutraveda reported a robust revenue of ₹33.60 crore and a net profit of ₹5.07 crore, representing a significant 110% year-on-year growth in sales. 

The company maintained strong profitability with an annual Operating Profit Margin (OPM) of 20.51% and a Net Profit Margin (NPM) of 15.08%. In the final half-year period (Oct 2025 – Mar 2026), the company reported revenue of ₹1,953.85 lakh (₹19.54 crore) with an OPM of 18.22%, reflecting stable operational efficiency as the business continues to scale.

In absolute terms, operating profit for FY26 increased by nearly 85%, rising from Rs. 3.72 crore in FY25 to Rs. 6.89 crore. Net profit stood at Rs. 5.07 crore, marking a 94% increase compared to Rs. 2.61 crore reported in the previous financial year.

The results reflect strong operational expansion compared to earlier years. The company has demonstrated rapid growth over the past three years, with sales growing at a compounded rate of approximately 127% and profits expanding at around 163%, reflecting increasing demand for contract manufacturing in the nutraceutical and Ayurveda segments.

Operationally, the company has continued to expand its manufacturing capabilities across multiple dosage formats such as capsules, tablets, oral liquids, and external preparations. Rising capacity utilization across these segments indicates strengthening order inflow from domestic clients as well as export-oriented merchant partners.

The company also maintains a relatively conservative capital structure, with a debt-to-equity ratio of around 0.12, which indicates limited financial leverage and provides flexibility for future expansion initiatives. Strong return metrics further highlight operational efficiency, with ROCE at 27.6% and ROE at 24.8%.

Following the announcement, Accretion Nutraveda Ltd shares traded at ₹289.00 on May 11, 2026, registering an intraday gain of 2.12% on the BSE SME platform. The stock touched a high of ₹289.80 during the session and remains close to its 52-week high of ₹300, while the 52-week low stands at ₹150.10.

The company currently commands a market capitalization of approximately ₹209 crore, with investors closely monitoring its growth trajectory in the fast-expanding nutraceutical manufacturing space.

Company Overview

Incorporated in 2021, Accretion Nutraveda Limited operates as a CDMO (Contract Development and Manufacturing Organization) focused on Ayurvedic and nutraceutical healthcare products. The company manufactures a wide range of formulations for domestic clients, merchant exporters, and international markets, positioning itself as a growing player in India’s health and wellness manufacturing ecosystem.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor.

The post Accretion Nutraveda Reports Robust FY26 Results with 110% Sales Growth; Stock Gains 2% appeared first on Trade Brains.